In this study, we noted a higher expression level of the ICGs (CTLA4, CD274, PDCD1C, HAVCR2, and LAG3) in the osteosarcoma patients categorized into the low‐risk group, which suggested that these patients could gain more benefits from the immune checkpoint blockade therapy. This evidence concerns the gene HAVCR2 and osteosarcoma.